Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
Severity of oral/mucosal burning pain/sensation · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Rajendran 2006 concluded the intervention reduced pain, but pain intensity evaluations were inadequately defined and from interview data, making mean scores difficult to interpret.
1 study · 29 participants
GRADE not reported
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes burning sensation (VAS 0-100) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline may leads to lower maximal mouth opening (interincisal distance) compared with spirulina (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Pentoxifylline showed no clear difference in oral mucositis (moderate to severe) compared with no treatment; GRADE not reported.
1 finding from 1 review
Severe intraventricular haemorrhage · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Periventricular leukomalacia · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of stay among survivors · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Necrotising enterocolitis · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).
1 finding from 1 review
Retinopathy of prematurity · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found